You're contacting media contact of this press release

Title: Exclusive Interview with Dr. David Brookes - Anatara Lifesciences (ASX:ANR)

 Adelaide, Australia, 28th Dec 2024 - Anatara Lifesciences has been working towards the release of a new complementary medicine for IBS sufferers. Anatara’s GaRP-IBS trial has progressed to Stage 2, with Stage 1 showing strong preliminary efficacy results. Patients on the low dose saw a 56% reduction in IBS-SSS scores, outperforming the placebo group by 20%. Promising news for IBS sufferers! Now recruitment of Stage 2 has hit a huge milestone this week!This interview with Executive Director Dr. David Brookes discusses this exciting phase in GaRP’s development. Q. Can you share the latest developments in Anatara’s GaRP-IBS clinical trial, particularly with the recent addition of sites in Adelaide and the Sunshine Coast?     Dr. Brookes: I was able to update on the trial in the recent ASX announcement on the 4th of December and at a webinar the following day that enrolment had reached approximately 60 with more than a further 25 involved in advanced screening. The trial’s momentum has been maintained with the new sites being important contributors. Stage 2 of the GaRP-IBS Phase II trial was designed with an anticipated minimum of 60 participants which we are pleased to be meeting and anticipate passing comfortably. Hence, the Company has announced a halt on recruitment from the 13th of December. Q. How have participant enrollments been progressing across all trial locations, and what does this mean for the overall study timeline? Dr. Brookes: The enrolments have continued across the 4 active sites at a rate that has allowed us to halt recruitment from the 13th of December as enrolments pass the anticipated minimal number of participants with a focus on a headline results readout early next year (1QCY25).  Q....

This press release is issued by King Newswire